Member Info for The_Paladin

Still no white smoke, but the reasonable forecast dates on fidelity.co.uk, suggest that we might be receiving an update later this month? Perhaps this may be announced on the company’s website, hence my daily check for information.

https://www.fidelity.co.uk/factsheet-data/factsheet/GB00B0381Z20-synairgen/news-key-dates-and-documents

It speaks volumes that there isn’t even perfunctory information concerning expected updates in available to investors.

To your credit Doc83, you have already done just that during the last two AGMs, together with a number of well-respected investors, who nowadays occasionally comment on this forum.

Synairgen will move their strategy forward, when it suits them. Past precedent shows that they won’t respond in any shape or form to investors’ comments or requests.

In any case, surely we will have some information regarding the launch of the P2 trials before the AGM date is announced? Otherwise, the implication may well be yet further delay?

Correction: Feb 2022

Hatter01.

I agree that an 8p valuation is meaningless to LTIs, whose shareholding depreciated by over 90% instantly, and as yet irredeemably in Feb 2024.

I also concur that the dearth of any measurable progress since then, borne out by the steady fall in share price since then is concerning.

That being said, a strategy has been in place for well over seven months. Coupled with this, diligent researchers on this forum have copiously pointed out the world wide need for a broad spectrum antiviral product like Synairgen.

However, the company really do need to begin the anticipated P2 trialling soon, if they are to maintain any credibility. They may well embark on an alternative path? Any positive development from here onwards would be welcome.

Most individuals expressing concern are frustrated investors caught up in the unfortunate Sprinter outcome, who have kept faith with their investment. As things have turned out, it might have been wiser to move on in mid 2022, when the share price showed something of a resurgence to 30p+? That opportunity has long gone, and soon we will know whether our faith in holding onto our investment will be repaid with positive news from the company? One way or another, it won’t be too long now!

GLALTIs.

Oddly, I have taken some encouragement from reading some recent comments here. Why have DB issued this assessment after 7 months?

Presumably, the analyst has worked for DB since the Numis acquisition? It would seem reasonable for him to have reissued an updated Synairgen broker’s note before now?

Has the analyst been prompted recently by the company, or by TFG perhaps, to begin following Synairgen again and to issue an initial assessment to lay down a marker?

This supposes that there are going to be developments ahead, and with them an increase in share price. It has happened with Synairgen before. In early January 2020, the share price was around the current level. Successive developments brought with them significant share price increases culminating in the post P2 moonshot, when the share price rose by 3OX the January 2020 value.

Given a successful outcome to the strategy from September 2023, we could well see success of this kind being repeated? Having brokers on board to monitor the progress and issue advice to investors is an essential part of this process.

I remain somewhat sceptical until we receive news from Synairgen on their strategy's progress. However, today’s note could well be the start of something provided it is followed by positive news on the P2 trials? Until that happens, there is little to discuss. I am guardedly optimistic, and shall continue to check each morning for that elusive RNS.

All IMHO. GLALTIs.

MrCosts.

Explained by Doc83 below. No real substance to it.

There is no 10% drop either. One small sell, amidst a number of small buys at around the current share price.

The next substantial RNS should be instructive? I have thought the same in the past, so I shall continue to wait, and see what eventually happens?

I will take 8p/Hold from DB rather than Ghia’s recent assessment. There is no update to underpin it, although I agree that there is probably a good reason for its introduction.

I shan’t mention trolls on this forum again, but will continue to filter their messages as before. I now believe that most contributors’ assessment of Sakura7 is correct. S/he initiated the most ludicrous conversation I have seen on a share discussion board.

I hope that today’s DB rating, will soon be followed by a significant update from Synairgen to upwardly reset the company’s ludicrous valuation, currently based on our cash reserve?

GLALTIs.

Manifesto.

Under AIM rules, 75% of all shareholders need to be in favour before delisting can happen. For obvious reasons, that scenario is not an option for the CEO and BOD to consider.

Even if the vast majority of private investors were favourably inclined towards delisting , TFG Holdings with their 28.3% shareholding, are in effective control of the process.

Fruitsnveg.

“I'll do me and you do you - none of us need to be told.”

Fine! That implies that we have more of your immature response to other contributors to look forward to. I am grateful that you at least indulged me with a sensible reply.

With regards to your labelling me and others as having nefarious reasons for contributing here, that is beyond a joke.

You recently stated that our uncommunicative CEO was well respected by BP companies. Do you have any evidence to validate that statement? I won’t counter by suggesting that you may have a hidden agenda in offering this information? However, it wouldn’t be unreasonable to make that deduction.

“ who proclaims that the cold unit trolls are being cruelly treated”

As ever, it is you who proclaims without fully understanding the other person’s point of view. Any perceived troll can effortlessly be filtered. Their opinions have zero effect on the share price so why indulge them with a pointless offensive response?

Many LTIs are genuinely concerned by zero communication from Synairgen since last September. It is the company’s total disregard of LTIs in particular that is inducing “doom and gloom”, nothing else! Their supporters were proclaiming “won’t be long now” in early 2023. There is no evidence to support any progress since then. By progress, I mean anything from Synairgen that had a positive effect on its share price.

GLALTIs

The accusations being put forward against contributors to a niche investor forum are pointless quibbles at best.

None of this dialogue will ever influence shareholders’ sentiment, so why bother to state it?

I read each contribution at face value initially. Should a series of comments from an individual strike me as being nonsense, then I have the option to filter the author. To date, very few contributors have fallen in that category since the migrations of less than helpful individuals to the advfn board some time ago.

The major issue regarding Synairgen, as I see it is the company’s perceived inaction over twenty six months. We have read about several successive incarnations of “forthcoming trials”, dialogues with significant partners, and appointments and departures of pointless major staff.

It is the company’s leadership that should be under major scrutiny. They are rewarding themselves with high salaries, and have produced nothing concrete, above speculation that is, to date in over two years.

Should we still be in the position where we are hoping for the best, but preparing for the worst regarding P2 trialling - due to having no idea whatsoever about the progress, if any, that has been achieved over the last seven months or so?

The company’s CEO has hardly raised his head above the parapet for more than two years! Is he still at the helm? If so it would be good to receive an update from him.

Rant over!

Should we receive promising news of the aforementioned P2 trials in the near future, I will be more than happy to apologise to this forum for sharing these grim thoughts. However, my view of the inappropriate way that Synairgen has disregarded its investors, LTIs in particular, will remain, whatever the future may bring.

GLALTIs.

Https://ih.advfn.com/stock-market/AMEX/nanoviricides-NNVC/stock-news/93768617/nanoviricides-reports-that-the-phase-i-nv-387-clin

MrCosts.

LTIs, like myself, are the wrong people to seek advice from. I have made the same error as yourself, in holding too much stock prior to the P3 trial outcome in Feb 2022. Further, in retrospect, I should have sold out and invested elsewhere when TFG Holdings added to their stake resulting in the only share price rise with an underlying cause in over two years.

Doc.Daneeka has provided a good summary of the last two years from an LTI's perspective. To summarise, after all this time, we are still waiting for a detailed announcement from Synairgen to launch their strategy. This needs to happen soon owing to the company's diminishing cash reserves. I am reading Spacman's contributions with interest. However, like all LTIs, my hopes are pinned on, hopefully, imminent news from the company concerning the P2 trials. For sure, they have not endeared themselves to LTIs by not issuing any updates for so long.

GLALTIs.

The following bullet points are from the investors’ page on Synairgen’s website.

* Pioneering science.

* Clinical Need - large and growing.

* Experienced leadership team.

* Wholly-owned and novel investigative product.

* World-class partners.

The first two are presumably the primary reasons that LTIs have remained invested throughout the underwhelming post-Sprinter era to date? This is true in my case.

Unfortunately, the combined experience of the leadership team has not been reflected in their actions over the last twenty six months, as many LTIs have pointed out recently.

However, the fourth and fifth points should attract the attention of short term investors. Are these valid, statements or is it yet more hyperbolic language from the company?

Some clarity from the CEO and BOD , especially with regard to the status of the P2 trials is by now long overdue.

All IMHO. GLALTIs.

Doc83.

The fact that shareholders, who care about the company and its future, requested more frequent feedback at the last AGM is significant.

Synairgen’s total disregard of a perfectly reasonable request speaks volumes about the arrogance of the CEO and BOD. I have no evidence, as such, but have long suspected that the company isn’t as well led as it ought to be? Obfuscation through a refusal to communicate is a means of covering up any lack of competence in the actions of the leadership group.

We will know soon enough, and can but hope that my thoughts turn out to be entirely misplaced, and that the company actually delivers appropriate P2 trials, as previously specified.

GLALTIs.

The longer the elapsed time from the last announcement, the more concerning it becomes for LTIs. The most recent periods of long silence from Synairgen have been followed by jam tomorrow statements, which have thus far led to nothing.

We are no longer informed about presentations, or significant staff changes. All we have on this forum is intelligent guesswork based on information from tangentially relevant articles that the best researchers are able to discover.

After seven months, with no news whatsoever from Synairgen, an update is by now long overdue. Hopefully, there will be no further excuses from our perennially disappointing CEO. GLALTIs.

Seriously though, he ought to be ashamed of himself. He is the CEO of a company, whose products and technology are used to treat seriously ill people.

Surely, the focus should be on development to ensure that everything moves ahead as quickly as possible? Instead, side hustles are set up to enable a small number of people to make money. The World is a sadder place for having people like them in it.

“How do people find these nuggets, impressive?”

IMHO, It is simply because they correspond to the outline strategy that was communicated last September. There is nothing definite about them until we receive an update affirming that the strategy is on track. If the company has managed to achieve their planned tasks without a hitch, we should be updated before the end of June.

GLALTIs.

Thank you captaincal.

I note that Hazel Pitt, the Director of Quality at Synairgen since Dec 2022, also has “#Open to Work” attached to her LinkedIn profile.

It would appear that Synairgen’s (undisclosed) strategy has evolved over the last two years or so. This is reflected by the recent gradual slimming down and reorganisation of the senior leadership team. The appointment of a CMO appears to have been a significant development.

Providing they can keep the P2 trials on track, without having to resort to additional funding, we have every chance of moving towards something of a recovery this year. In my view, it will take a liaison with a significant external partner to achieve anything near to the MCap reached during early 2022.

I am not pinning any hopes on a recovery until I am fully aware of what has been going on behind the scenes over the last seven months.

GLALTIs.

Thanks Spacman.

Does this mean that Richard Francis is Hazel Pitt’s line manager? It was reported on this forum at the time of the last AGM that Richard Francis was undertaking external consulting, as he didn’t have enough to do within the company?

IMHO after two years in the wilderness, it is high time that investors were offered more clarity as to the company’s aspirations. The reporting of concrete achievements to date is similar to what might have been expected during the pre-Sprinter years.

On the positive side, a definite narrative storyline is by now well established. Mostly, thanks to Brooke Clarke, I gather? The coming months will tell us for once and for all whether the company has achieved a breakthrough? Otherwise, it will be more “working hard and at haste” obfuscation from you know who.